TB-500 Research for Cardiac Repair
An evidence-based overview of research examining TB-500 in the context of cardiac repair. This page synthesizes findings from peer-reviewed literature.
Research Summary
Thymosin beta-4 has shown significant cardioprotective effects in animal models of myocardial infarction. Bock-Marquette et al. (2004, Nature) demonstrated that Tb4 activates the ILK-Akt cell survival pathway. Research from UK (Oxford), Germany, and USA shows reduced infarct size, prevention of cardiac rupture, and improved survival in mouse models. The peptide promotes epicardial progenitor cell migration, which may contribute to cardiac regeneration. A Phase 1 human cardiac trial (NCT01311518) was completed but results showed limited efficacy. The challenge of delivering peptides to cardiac tissue remains significant.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Cardiac Repair
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. TB-500 may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.